Can DHEA cause gynaecomastia? This is an important question for any man considering DHEA supplementation. Dehydroepiandrosterone (DHEA) is a steroid hormone precursor that converts to both androgens and oestrogens in the body. In the UK, systemic DHEA products are largely unlicensed, yet many men obtain them online for purported anti-ageing or performance benefits. Because DHEA can be aromatised to oestrogens in peripheral tissues, it is biologically plausible that it may disrupt the androgen-to-oestrogen balance in breast tissue, potentially triggering gynaecomastia — particularly in susceptible individuals. This article explains the mechanism, risk factors, warning signs, and what UK guidance recommends.

What Is DHEA and How Is It Used in the UK?

DHEA is an adrenal steroid hormone precursor; in the UK, only the intravaginal preparation prasterone (Intrarosa) holds an MHRA licence, while systemic DHEA supplements are generally unlicensed and their supply may be unlawful.

Dehydroepiandrosterone (DHEA) is a naturally occurring steroid hormone produced primarily by the adrenal glands. It serves as a precursor to both androgens (male sex hormones such as testosterone) and oestrogens (female sex hormones such as oestradiol). Circulating DHEA levels peak in early adulthood and decline progressively with age — a process sometimes referred to as adrenal ageing.

In clinical medicine, DHEA is occasionally used in the UK for specific licensed indications. The prescription-only, intravaginal preparation prasterone (Intrarosa) is licensed by the MHRA for the treatment of moderate to severe vulvovaginal atrophy in postmenopausal women (see the electronic Medicines Compendium SmPC for full prescribing information). Outside of this licensed indication, DHEA is not routinely prescribed on the NHS.

UK regulatory status of DHEA products

DHEA is generally classified as a medicinal product by function under UK medicines legislation and is not licensed for systemic use in the UK. Products sold online or marketed as supplements for anti-ageing, libido, or performance enhancement are typically unlicensed medicines, and their supply in the UK may be unlawful. Many such products are unregulated imports of unknown quality, purity, and dose. Consumers purchasing these products — particularly from international online sources — may be unaware of the legal position or the potential hormonal consequences, including the risk of gynaecomastia in men.

Common claims made for such products include:

• Boosting energy and libido

• Supporting muscle mass and athletic performance

• General anti-ageing benefits

None of these indications are supported by robust clinical evidence or approved by UK regulatory authorities.

The Link Between DHEA and Gynaecomastia

DHEA can be aromatised to oestrogens in peripheral tissues, creating a relative oestrogen excess that may stimulate male breast glandular tissue, though direct causal evidence from large trials is currently lacking.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity in breast tissue. Understanding how DHEA may contribute to this condition requires an appreciation of its hormonal metabolism.

When DHEA is ingested or produced endogenously, it undergoes peripheral conversion into both androgens and oestrogens through enzymatic pathways in tissues such as adipose tissue, liver, and skin. In some individuals — particularly those with higher levels of aromatase enzyme activity — a greater proportion of DHEA may be converted to oestradiol and oestrone rather than testosterone. This relative increase in oestrogenic activity can stimulate breast glandular tissue, potentially contributing to gynaecomastia.

It is important to note that robust, large-scale randomised controlled trial evidence directly linking DHEA supplementation to gynaecomastia is lacking. The association is based on biological plausibility, pharmacological reasoning, and case reports rather than definitive causal proof. The current evidence suggests it is biologically plausible that DHEA could contribute to gynaecomastia in susceptible individuals, particularly at higher doses. Proposed mechanisms include:

• Increased aromatisation of DHEA to oestrogens in peripheral tissues

• Potential suppression of endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis, though effects at commonly used supplement doses are inconsistent

• Relative oestrogen excess relative to androgen activity at breast tissue receptors

DHEA products are often available in doses (25–100 mg) that may significantly exceed physiological levels, which could amplify the risk of hormonal imbalance. Men taking DHEA who notice breast tenderness, swelling, or nipple sensitivity should consider this as a potential contributing factor and seek medical advice. For further information on the recognised causes of gynaecomastia, refer to NICE Clinical Knowledge Summary (CKS): Gynaecomastia.

Who Is Most at Risk of Hormonal Side Effects?

Older men, men with obesity, and those with liver disease are at highest risk because reduced testosterone levels and increased aromatase activity amplify DHEA's conversion to oestrogens.

Not everyone who takes DHEA will experience gynaecomastia or other hormonal side effects, but certain groups are at considerably higher risk. Understanding these risk factors can help individuals and clinicians make more informed decisions.

Men are at greater risk than women of developing gynaecomastia from DHEA, given that even modest increases in oestrogen relative to androgen levels can disrupt the hormonal balance in breast tissue. Within the male population, the following groups warrant particular caution:

• Older men: Age-related decline in testosterone production means the androgen-to-oestrogen ratio is already reduced. DHEA use may tip this balance further towards oestrogen dominance.

• Men with obesity: Adipose tissue is rich in aromatase enzyme, increasing the conversion of DHEA to oestrogens. Higher body fat percentage directly amplifies oestrogenic effects.

• Men with liver disease: Impaired hepatic metabolism can alter steroid hormone clearance, prolonging exposure to oestrogenic metabolites.

• Men taking other hormonal or interacting medicines: Concurrent use of anabolic steroids, antiandrogens (e.g., spironolactone), or certain antifungals (e.g., ketoconazole) may compound hormonal disruption. Both spironolactone and ketoconazole are independently recognised as causes of gynaecomastia (see BNF monographs).

• Adolescents and young men: Hormonal systems are more sensitive during developmental stages, and unsupervised use carries additional risks.

Individuals with a personal or family history of hormone-sensitive conditions should exercise particular caution. Men with current or previous prostate cancer, or unexplained changes in PSA, should seek specialist advice before using any androgenic or oestrogenic precursor, as evidence regarding DHEA's effects on prostate disease is limited. Self-prescribing without professional oversight is strongly discouraged.

For a comprehensive UK-aligned list of risk factors and medicines associated with gynaecomastia, refer to NICE CKS: Gynaecomastia and the NHS Gynaecomastia page.

When to Seek Medical Advice About Breast Changes

Any new breast lump, tenderness, nipple discharge, or skin change in a man requires prompt GP assessment; NICE NG12 recommends an urgent 2-week-wait referral for men aged 30 and over with an unexplained breast lump.

Any new or unexplained breast change in a man should be assessed by a healthcare professional promptly. While gynaecomastia is most commonly benign, it is essential to rule out other causes — including, rarely, male breast cancer — before attributing symptoms to DHEA or any other product.

Contact your GP if you notice any of the following:

• Swelling or enlargement of one or both breasts

• Breast tenderness or pain, particularly around the nipple area

• A firm or rubbery lump beneath the nipple

• Nipple discharge of any kind

• Skin changes over the breast, such as dimpling or redness

• Asymmetrical breast changes, especially if only one side is affected

Urgent referral (2-week wait)

In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent suspected cancer referral (to be seen within 2 weeks) for:

• Men aged 30 and over with an unexplained breast lump (with or without pain)

• Men aged 50 and over with unilateral nipple discharge, nipple retraction, or other nipple changes

• Anyone with skin changes over the breast suggestive of cancer

If you have any of these features, do not delay seeking medical attention.

What your GP may arrange

Your GP will typically take a thorough history — including any supplement or medicine use — and may arrange blood tests. These commonly include testosterone, oestradiol, LH, FSH, prolactin, thyroid function, liver function tests (LFTs), and urea and electrolytes (U&Es). Where a testicular or other tumour is suspected, serum hCG should also be measured, and testicular examination (with ultrasound if indicated) may be arranged. In some cases, referral to an endocrinologist or breast clinic is appropriate, where imaging such as ultrasound or mammography may be performed if features are atypical or suspicious.

If you are currently taking DHEA and develop breast changes, it is advisable to stop the product and inform your GP, bringing the packaging if possible. Do not restart use without professional guidance. Early assessment allows for timely management, which may include watchful waiting, addressing underlying hormonal imbalances, or referral for specialist review.

Safer Alternatives and MHRA Guidance on DHEA Products

The MHRA advises caution when purchasing hormonal products online, as most systemic DHEA supplements are unlicensed; evidence-based alternatives include lifestyle modification and NHS-managed treatment of underlying hormonal conditions.

As noted above, DHEA is generally classified as a medicinal product by function in the UK and is not licensed for systemic use. Products sold online for anti-ageing, libido, or performance purposes are typically unlicensed medicines, and their supply in the UK is generally unlawful. Many are unregulated imports of unknown quality, with inconsistent dosing and undisclosed risks. The MHRA advises consumers to exercise caution when purchasing any hormonal product online, particularly from unregulated international sources. Further guidance is available via the MHRA's advice on buying medicines online.

Products claiming to boost testosterone, enhance libido, or reverse ageing through hormonal manipulation should be viewed critically. The MHRA Yellow Card scheme — the UK's pharmacovigilance reporting system — allows both patients and healthcare professionals to report suspected adverse reactions to medicines and supplements. Anyone who experiences side effects they believe may be related to DHEA is encouraged to submit a report at https://yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Evidence-based alternatives

For those seeking to address symptoms commonly associated with declining hormone levels — such as fatigue, low mood, or reduced libido — the following approaches are supported by evidence:

• Lifestyle modifications: Regular physical activity, balanced nutrition, adequate sleep, and stress management have well-documented benefits on hormonal health and general wellbeing

• Addressing underlying conditions: Conditions such as hypothyroidism, hypogonadism, or depression should be properly investigated and treated through NHS pathways

• NICE-recommended treatments for postmenopausal symptoms: For postmenopausal women with genitourinary syndrome of menopause (GSM), NICE NG23 (Menopause) recommends topical (local) vaginal oestrogens as an effective and safe option. Prasterone (Intrarosa) is separately licensed by the MHRA as a prescription-only intravaginal treatment for vulvovaginal atrophy, though it is not specifically recommended by name in current NICE guidance.

In summary, while it is biologically plausible that DHEA may contribute to gynaecomastia — particularly in susceptible individuals — robust causal evidence remains limited. The risk is best managed through awareness, avoidance of unlicensed products, and appropriate medical oversight. Anyone considering DHEA should discuss this with their GP beforehand, rather than using unregulated products obtained online.

Frequently Asked Questions